This application note describes the development of our 2D OncoSignature™ Long-Term Assay (LTA) drug discovery service which enables the profiling of slower acting or epigenetic drugs across a diverse, clinically relevant panel of cell lines.
For research use only. Not for use in diagnostic procedures.
2D OncoSignature™ long-term assay: extending the reach of cell panel screens